193
views
1
recommends
+1 Recommend
1 collections
    0
    shares
      Version and Review History
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Liraglutide vs. Lifestyle Intervention in Obesity Treatment: Pros and Cons

      Preprint
      In review
      research-article
        1 , , 1
      ScienceOpen Preprints
      ScienceOpen
      liraglutide, saxenda, lifestyle changes, weight loss, diet, obesity, GLP-1 receptor agonist
      Bookmark

            Abstract

            The increasing prevalence of obesity continue to trigger a cascade of other non-communicable medical conditions and further cripple healthcare financial budgets worldwide. This preventable chronic disease is a global public health concern and has been the center of past, present and future research. As an adjunct to lifestyle intervention, the Food and Drug Administration (FDA) has currently approved five anti-obesity medications. However, skepticism surrounding the prescription of medication is presented based on historic concerns of previously withdrawn medication.

            Liraglutide is among the newly approved anti-obesity medications and has shown favorable weight loss results. The choice of treatment requires a selective determination based on the specific patient population, existing chronic condition(s) and individual preferences.

            The goal of this review is to highlight the advantages and disadvantages of liraglutide use compared to lifestyle intervention in treating obesity. This would help individuals make informed decisions in choosing the most suitable option for treating obesity.

            It can be concluded that there is no single-handed approach to combat obesity. Regardless of the chosen option, individuals need to be consistent with behavioral changes and exercise in order to effectively treat and possibly eradicate this global epidemic.

            Content

            Author and article information

            Journal
            ScienceOpen Preprints
            ScienceOpen
            28 August 2021
            Affiliations
            [1 ] California Institute of Behavioral Neurosciences and Psychology
            Author notes
            Article
            10.14293/S2199-1006.1.SOR-.PPQFKQQ.v1
            20a1a9c6-806f-4824-b0e4-9e19ad34a174

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .


            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            Medicine
            liraglutide,saxenda, lifestyle changes,weight loss,diet,obesity,GLP-1 receptor agonist

            Comments

            Comment on this article